@prefix biolink: .
@prefix ns1: .
@prefix this: .
@prefix sub: .
@prefix schema: .
@prefix np: .
@prefix dct: .
@prefix rdf: .
@prefix xsd: .
@prefix rdfs: .
@prefix orcid: .
@prefix prov: .
@prefix npx: .
sub:Head {
this: a np:Nanopublication;
np:hasAssertion sub:assertion;
np:hasProvenance sub:provenance;
np:hasPublicationInfo sub:pubinfo .
}
sub:assertion {
biolink:category biolink:Disease .
sub:association a rdf:Statement;
rdf:object ;
rdf:predicate biolink:treats;
rdf:subject ;
rdfs:label "\"Quinine sulfate is contraindicated in patients with the following: Prolongation of QT interval ( 4 Glucose-6-phosphate dehydrogenase (G6PD) deficiency ( 4 Myasthenia gravis ( 4 Known hypersensitivity to quinine, mefloquine, or quinidine ( 4 Optic neuritis ( 4 Quinine sulfate is contraindicated in patients with the following: * Prolonged QT interval. One case of a fatal ventricular arrhythmia was reported in an elderly patient with a prolonged QT interval at baseline, who received quinine sulfate intravenously for P. falciparum [see WARNINGS AND PRECAUTIONS ( 5.3 * Glucose-6-phosphate dehydrogenase (G6PD) deficiency. * Hemolysis can occur in patients with G6PD deficiency receiving quinine. * Known hypersensitivity reactions to quinine. * These include, but are not limited to, the following [see WARNINGS AND PRECAUTIONS ( 5.6 * Thrombocytopenia * Idiopathic thrombocytopenia purpura (ITP) and Thrombotic thrombocytopenic purpura (TTP) * Hemolytic uremic syndrome (HUS) * Blackwater fever (acute intravascular hemolysis, hemoglobinuria, and hemoglobinemia) * Known hypersensitivity to mefloquine or quinidine: cross-sensitivity to quinine has been documented [see WARNINGS AND PRECAUTIONS ( 5.6 * Myasthenia gravis. Quinine has neuromuscular blocking activity, and may exacerbate muscle weakness. * Optic neuritis. Quinine may exacerbate active optic neuritis [see ADVERSE REACTIONS ( 6\"";
biolink:provided_by ;
biolink:relation schema:MedicalContraindication .
biolink:category biolink:Drug .
}
sub:provenance {
sub:assertion prov:wasAttributedTo orcid:0000-0002-1468-3557 .
}
sub:pubinfo {
sub:sig npx:hasAlgorithm "RSA";
npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB";
npx:hasSignature "T3N3TGK5kHu+neLOtZXrtOnpSw3grcBqr1rVJrHngOeardHubJl2iz+jiYJ8cgDP9/IiglORHW1fpPFWcjjz+QIwrLDtmxl9ORr30gi+JcjE+QHuVh/QNeZCFlfK/GrE32Gig9oSpEvtA1qVESS+9oyxeuts3EJg0u9U+qdz2KY=";
npx:hasSignatureTarget this: .
this: dct:created "2021-08-23T18:44:18.224+02:00"^^xsd:dateTime;
dct:creator orcid:0000-0002-1468-3557;
ns1:wasCreatedFromProvenanceTemplate ;
ns1:wasCreatedFromPubinfoTemplate ;
ns1:wasCreatedFromTemplate .
}